Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 42.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 335,913 shares of the company's stock after buying an additional 100,257 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.31% of Tango Therapeutics worth $2,882,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. acquired a new position in shares of Tango Therapeutics during the 2nd quarter worth about $90,000. Bank of New York Mellon Corp lifted its position in shares of Tango Therapeutics by 12.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 141,623 shares of the company's stock worth $1,215,000 after buying an additional 15,373 shares during the last quarter. Simplicity Wealth LLC boosted its holdings in shares of Tango Therapeutics by 59.6% in the 2nd quarter. Simplicity Wealth LLC now owns 43,041 shares of the company's stock valued at $369,000 after buying an additional 16,080 shares in the last quarter. Artal Group S.A. purchased a new position in shares of Tango Therapeutics in the 1st quarter valued at $17,427,000. Finally, Paloma Partners Management Co acquired a new stake in Tango Therapeutics during the 1st quarter worth $80,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Rock Ventures Iv L.P. Third sold 550,171 shares of the business's stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $9.79, for a total transaction of $5,386,174.09. Following the sale, the insider now owns 18,651,304 shares of the company's stock, valued at $182,596,266.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 1,680,311 shares of company stock valued at $17,042,393. Corporate insiders own 6.30% of the company's stock.

Tango Therapeutics Trading Down 3.4 %

NASDAQ TNGX opened at $6.55 on Friday. The business's 50 day moving average is $9.26 and its two-hundred day moving average is $8.54. Tango Therapeutics, Inc. has a 12-month low of $5.15 and a 12-month high of $13.01.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.10. The firm had revenue of $19.88 million during the quarter, compared to analysts' expectations of $7.39 million. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. Research analysts anticipate that Tango Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TNGX. HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Tango Therapeutics in a research note on Tuesday, July 9th. Jefferies Financial Group started coverage on Tango Therapeutics in a research report on Wednesday, July 17th. They issued a "buy" rating and a $19.00 price target on the stock. Finally, Wedbush increased their price objective on Tango Therapeutics from $11.00 to $13.00 and gave the stock an "outperform" rating in a research report on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $15.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.